6533b871fe1ef96bd12d196d
RESEARCH PRODUCT
Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study.
Alexandra NietersGeorgina MbisaN BeckerNazzarena LaboP. BofettaYolanda BenaventeAnthony StainesPierluigi CoccoPaul BrennanDenise WhitbyDelphine CasabonneS De SanjoséMarc MaynadiéLenka Foretovasubject
AdultMaleCancer ResearchAdolescentvirusesShort CommunicationserologylymphomaAntibodiesSerologyhuman herpes virus 8Young AdultHerpes virusAntigenhemic and lymphatic diseasesLymphoma Primary EffusionmedicineHumansChildKaposi's sarcomaAntigens ViralSarcoma KaposiAgedAged 80 and overbiologybusiness.industryCastleman DiseaseLymphoma Non-HodgkinCase-control studyInfant Newbornvirus diseasesInfantMiddle Agedmedicine.diseaseVirologyLymphomaEuropeOncologyLytic cycleKaposi's sarcoma-associated herpes virusCase-Control StudiesChild PreschoolImmunologyHerpesvirus 8 Humanbiology.proteinFemaleepidemiologyAntibodybusinessdescription
Background: Kaposi's sarcoma-associated herpes virus is associated with primary effusion lymphoma and multicentric Castleman's disease. Methods: Seropositivity to lytic and latent Kaposi's sarcoma herpes virus (KSHV) antigens were examined in 2083 lymphomas and 2013 controls from six European countries. Results: Antibodies against KSHV latent and lytic antigens were detectable in 4.5% and 3.4% of controls, respectively, and 3.6% of cases (P>0.05). The KSHV seropositivity was associated with splenic marginal zone lymphoma (SMZL) (odds ratio (OR)=4.11, 95% confidence interval (CI)=1.57–10.83) and multiple myeloma (OR=0.31, 95% CI=0.11–0.85). Conclusion: The KSHV is unlikely to contribute importantly to lymphomagenesis among immunocompetent subjects. However, the observed association with SMZL may underline a chronic antigen mechanism in its aetiology.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-09-29 | British journal of cancer |